Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PETX

Aratana Therapeutics (PETX) Stock Price, News & Analysis

Aratana Therapeutics logo

About Aratana Therapeutics Stock (NASDAQ:PETX)

Advanced Chart

Key Stats

Today's Range
$4.92
$4.92
50-Day Range
$4.92
$4.92
52-Week Range
$3.30
$7.16
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$241.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PETX Stock News Headlines

PETX_old Historical Data
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
5 Stocks Under $10 to Trade for Big Breakouts
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
See More Headlines

PETX Stock Analysis - Frequently Asked Questions

Aratana Therapeutics Inc (NASDAQ:PETX) posted its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative trailing twelve-month return on equity of 12.99%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Corcept Therapeutics (CORT), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
11/01/2018
Today
7/14/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PETX
CIK
1509190
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.72 million
Net Margins
-33.47%
Pretax Margin
N/A
Return on Equity
-12.99%
Return on Assets
-10.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.66
Quick Ratio
5.32

Sales & Book Value

Annual Sales
$35.41 million
Price / Sales
6.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.07 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
49,000,000
Free Float
N/A
Market Cap
$241.08 million
Optionable
Optionable
Beta
1.40
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:PETX) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners